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ABSTRACT 
The ultimate goal of comparative effectiveness research 
(CER) is to develop and disseminate evidence-based 
information about which interventions are most effective 
for which patients under what circumstances. To achieve 
this goal it is crucial that researchers in methodology 
development find appropriate methods for detecting the 
presence and sources of heterogeneity in treatment effect 
(HTE). Comparing with the typically reported average 
treatment effect (ATE) in randomized controlled trials and 
non-experimental (i.e., observational) studies, identifying 
and reporting HTE better reflect the nature and purposes 
of CER. Methodologies of CER include meta-analysis, 
systematic review, design of experiments that 
encompasses HTE, and statistical correction of various 
types of estimation bias, which is the focus of this review.  
 
 
 
INTRODUCTION—THE RELEVANCE OF CER IN HEALTH CARE REFORM 
 
The American Reinvestment and Recovery Act boosts the funding for Comparative effectiveness 
research (CER), which is deemed to hold significant promise to improve health care quality. 
Nevertheless, it faces some significant methodological challenges in fulfilling this promise. By 
definition, CER is “the conduct and synthesis of research comparing the benefits and harms of 
different interventions and strategies to prevent, diagnose, treat and monitor health conditions in 
‘real world’ settings” (Federal Coordinating Council 2009). The objective of CER is to aid decision-
makers to make evidence-based decisions to improve health care at both the population and 
individual levels. Thus, as a tool for CER, traditional randomized controlled trials (RCTs) are limited by 
poor generalizability. Observational studies in “real world” settings suffer from unmeasured 
confounding bias. Meta-analyses are complicated by heterogeneity of study populations and 
interventions. Some efforts have been made to overcome these methodological limitations of CER, 
such as innovative trial designs, propensity scores or instrumental variables methods for 
observational data analyses, and Bayesian meta-analyses.   
 
The ultimate goal of CER is to predict “which interventions are most effective for which patients 
under specific circumstances”, which coincides with the goal of the federal initiative for 
personalized health care. A broad definition of personalized medicine includes “all factors that 
distinguish an individual’s health characteristics and risks, including family history, clinical data, 
behavioral factors, and genomics when applicable” (Snyderman and Dinan 2010). In the era of 
personalized medicine, to directly address the goal of CER, there is a call for CER methodologies 
that can estimate the treatment effect at the individual patient level (Basu 2009). 
 
The need for individualized CER (iCER) is most prominent for diseases with heterogeneous treatment 
effect (HTE).  The development of iCER methodology will help to clarify which forms of evidence are 
sufficiently informative for a specific patient  (Garber and Tunis 2009). 
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CURRENT CER METHODS AND FRAMEWORKS RELATED TO ICER 
 
A Framework for Causal Inference 
The main problem with empirical analyses of treatment response, in RCTs or observational studies, is 
the non-observability of counterfactual outcomes. Studies of CER aim to predict outcomes that 
would occur if different treatment strategies were applied to a population. The Neyman-Rubin-
Holland tradition, or the Rubin Causal Model (RCM), is becoming the mainstay of causal inference 
in both RCTs and observational studies. Denote the potential outcome by Yi(A) if individual i is 
exposed to treatment alterative A. In a two-arm RCT, an intervention (A=1) is compared with 
placebo or control condition (A=0). A person is randomly assigned to one of the alternatives so that 
one of the Yi(A) is not observed. Individual level causal effects are defined by Yi(1) – Yi(0).  Random 
assignment leads to the direct estimate of E[Yi(0)] for the treated group using observed outcomes in 
the control group. The RCM allows for general heterogeneity in treatment responses and for direct 
handling of complications, such as noncompliance with assigned treatment. The treatment 
assignment mechanism is a stochastic rule governing the actual receipt of an alternative. It can be 
a known or an unknown function independent of potential outcomes, or a function dependent on 
potential outcomes. Different treatment assignment mechanisms require different analytical 
methods for estimating treatment effects.   
 
In observational studies, treatments are rarely randomly assigned. Thus corrections for overt and 
hidden biases have to be made under certain assumptions to produce valid inference on causal 
effects. Much of the recent development in the statistics literature for estimating average 
treatment effects (ATE) and bias correction builds on the work by Rubin, Rosenbaum and others 
(Rubin 1973; Rosenbaum and Rubin 1983; Heckman, Ichimura et al. 1998).  Applicable in a special 
case, variously referred to as unconfoundedness, exogeneity, ignorability, or selection on 
observables, these methods can be grouped into five categories: (i) estimating the unknown 
regression functions of the outcome; (ii) matching on covariates; (iii) propensity score methods; (iv) 
combination of the above; and (v) Bayesian methods (Imbens 2004). 
 
A parallel literature in econometrics for program evaluation was developed, with a focus on issues 
of endogeneity, or self-selection, when the unconfoundedness assumption is violated. Individuals 
who choose to enroll in a program are, by definition, different from those who choose not to enroll. 
Without unconfoundedness, five general categories of estimation methods have been summarized 
by Imbens and Wooldridge (2009).  These methods are: (a) sensitivity analyses; (b) bound analyses; 
(c) instrumental variables (IV) with exogeneity and exclusion restrictions; (d) regression discontinuity 
designs; and (e) a set of methods referred to as difference-in-differences. 
 
 Estimand and Hypothesis Testing 
In any evaluation study, the primary objective of estimation must be made explicit. Table 1 
summarizes the estimands of traditional CER in the simple case with two treatment options.  Well-
conducted RCTs estimate average treatment effects (ATEs) between treated and control groups. If 
ATEs can be generalized to the population it becomes the population ATEs (PATEs, τPATE). The PATE 
provides answers to policy questions such as “what would happen if entire population was subject 
to the intervention as compared to what would happen if the entire population was not subject to 
the intervention?” Such global estimates may not always be of interest. A second quantity of 
interest that has received much recent attention is the average treatment effect on the treated 
(ATT), which is the mean effect for those who actually were treated. Population ATTs (PATTs, τPATT) 
are useful when an intervention is not applicable to the entire population.  When estimates are 
adjusted by persons’ characteristics (Xi), such as women aged 65 and above with histories of 
depression, ATEs and ATTs become conditional ATEs (CATEs) and conditional ATTs (CATTs). When a 
pre-specified subgroup is the target of interest, estimates are CATEs in a subpopulation (CATE-S).  
Marginal q-th quantile treatment effect (MQTE-q, τq) is the difference between Yi(1) and Yi(0) at the 
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q-th quantile of the marginal distributions ( )1(1)YF q−  and ( )1(0)YF q− .  This quantity is particularly useful 
for continuous measures with varying treatment effects by the level of the outcome. Imbens and 
Woodridge (2009) point out issues of interpretation for this estimate. First, unless there is perfect rank 
correction between the potential outcomes, the two marginal distributions will not be the same. 
Second, the MQTE-q will not be the same as unit level q-th quantile treatment effect (UQTE-q, qτ ), 
which is based on the joint distribution of the potential outcomes ( )1(1) (0)Y YF q− − . The problem with 
UQTE-q is that qτ is not point identified without assumption of the rank correlation between the 
potential outcomes even in RCTs. Imbens and Angrist (1994) define a local ATE (LATE, τLATE) that is 
estimable using IV under very weak conditions. For example, in the case where the treatment 
indicator, Ai, is binary and a valid instrument, Zi, is binary, they show that, under the assumption of 
monotonicity, the estimated treatment effect, LATE ,τ is for the subpopulation that is affected by the 
instrument. However, this subpopulation is generally not identifiable. In this example, potential 
treatment options received, Ai(0) and Ai(1), depends on the particular instruments used for 
estimation (“compliers” in their nomenclature, whose treatment choice can be “manipulated” 
based on the values of the instrument).   
 
Hypothesis testing in CER concentrates on the null hypothesis that the estimand of interest is zero. In 
cases where τPATE is zero, it may be of interest to test whether there is positive treatment effect in a 
subpopulation, by observable covariates, or by the quantiles of the potential outcomes. This is 
highly relevant to iCER because, to make a treatment decision for a specific patient, a clinician 
needs to have evidence of the efficacy of alternative options based on a sample of other 
individuals for whom both outcome and covariate information are available before s/he can apply 
it to a new patient. Such information is not summarized by τPATE. Addressing the uncertainty of such 
decision rules is a new and growing literature. 
 
Table 1. Estimands of Interest in CER 
Estimand Definition 
Population Average Treatment Effect 
(PATE) 
[ ]PATE (1) (0)i iτ E Y Y= −  
PATE on the Treated (PATT) PATT (1) (0) 1i i iτ E Y Y A⎡ ⎤= − =⎣ ⎦  
Conditional Average Treatment Effect in 
the sample (CATE) CATE 1
1 (1) (0)
N
i i i
iN
τ E Y Y X
=
⎡ ⎤= −∑ ⎣ ⎦  
CATE on the Treated in the sample 
(CATT) CATT | 1
1
1
(1) (0) 1,
i Ai
N i i i i
τ E Y Y A X
=
⎡ ⎤= − =∑ ⎣ ⎦  
CATE in a subpopulation (CATE-S) CATE-S
:
1 (1) (0)
S i
i i i
i X SN
τ E Y Y X
∈
⎡ ⎤= −∑ ⎣ ⎦  
CATE on the Treated in a subpopulation 
(CATT-S) CATT-S | 1:
1 (1) (0) 1,
S i i
i i i i
i A X SN
τ E Y Y A X
= ∈
⎡ ⎤= − =∑ ⎣ ⎦  
Marginal q-th quantile treatment effect 1 1(1) (0)( ) ( )q Y Yτ F q F q
− −= −
 
Unit level q-th quantile treatment effect 1(1) (0)( )q Y Yτ F q
−
−=
 
Local Average Treatment Effect (LATE) LATE (1) (0) (0) 0, (1) 1i i i iτ E Y Y A A⎡ ⎤= − = =⎣ ⎦  
 
Sources of Heterogeneity in Treatment Effect (HTE) 
Responses to treatment for an individual or a group may depart from the population average due 
to differences in susceptibility, vulnerability to adverse side effects and utilities for different 
outcomes (Kravitz et al, 2004). Heterogeneity in treatment responses is the magnitude of the 
variation of individual or group treatment effects across a population. By estimating this variation, a 
clear distinction can be drawn on whether one treatment is superior to the other for everybody in 
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the population or whether one treatment is superior to the other for an average or typical person in 
the population.  
 
Adaptive Treatment Strategy and Time-varying Covariate 
Robins pioneered estimation of causal effect of a time-varying treatment in observational studies 
(Robins 1986). He and his colleagues introduced three methods under sequential ignorability: the 
inverse-probability-of-treatment weighted (IPTW) estimator, g-estimation of structural nested 
models, and the iterative conditional expectations estimator (Hernán, Brumback et al. 2001).  
Extensions of these estimators to cases with unmeasured confounder or censoring have been 
proposed (Brumback, Hernán et al. 2004; Bryan, Yu et al. 2004).  In recent years, attention has 
shifted to identifying optimal treatment sequence in an adaptive experiment. Murphy developed 
an iterative minimization method based on the dynamic programming or backwards induction 
principle (Murphy 2003).  Robins does so using g-estimation in structural nested mean models 
(Robins 2004).  Moodie et al. demonstrate that these two methods are closely related (Moodie, 
Richardson et al. 2007) and Dawson and Lavori argue that a sequential Bayesian predictive 
inference method is more efficient than the marginal mean approach (Dawson and Lavori 2008).  
 
Counterfactual Choice Probabilities and Decision Theories 
McFadden initiated the parametric random utility models to describe observed discrete-choice 
behavior and to predict the choices that a person would make in counterfactual choice settings 
(McFadden 1974). Since then much work was done to advance the field to include more tractable 
models with less severe preference assumptions (Train 2003). A distinct and innovative literature 
builds on the basic structure of discrete choice models using observed choice probabilities to 
partially infer the distribution of types of persons in the population (Manski 2007; Hirano and Porter 
2009). The results are then used to predict behaviors in unrealized choice settings. This literature is 
very much in progress and relevant to iCER because it studies the problem faced by a clinician or 
an experimental designer: a clinician or patient has to make a choice given limited information 
derived from another population. 
 
Pragmatic Clinical Trial 
Clinical trials for which “the hypothesis and study design are developed specifically to answer the 
questions faced by decision makers are called pragmatic or practical clinical trials (PCTs)” (Tunis, 
Stryer et al. 2003). Different from RCTs, PCTs compare practical interventions, include diverse 
populations in diverse practice settings, and collect data on a broad range of health outcomes. 
The former is explanatory to aid our understanding of an intervention; and the latter is pragmatic to 
aid our decision on preferred intervention for a patient, i.e., PCTs are designed to meet the needs 
of decision makers. NIMH funded several large-scale PCTs, including STAR*D for depression, STEP-BD 
for bipolar disorder, and CATIE for schizophrenia and Alzheimer’s disease (Insel 2006).  
 
After two international meetings on PCT design issues, a new tool, PRECIS, to assist trialists in making 
design decisions that are consistent with their stated purpose has been developed (Thorpe, 
Zwarenstein et al. 2009). PRECIS evaluates 10 domains of trial design with graphics to determine 
how generalizable results of a trial are. These 10 domains are: participants, flexibility of the 
intervention under evaluation, intervention practitioner expertise, comparison intervention, 
comparison intervention provider expertise, follow-up intensity, primary outcome, participant 
compliance/adherence, practice fidelity, and analysis of outcome. We believe the tool can also 
be used to evaluate the generalizability of an observational study.  
 
DISCUSSION 
 
Not all methodologies in CER are relevant to iCER because the two frameworks take on different 
perspectives: the former of a population and the latter of an individual. However, the methods 
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reviewed above are related to iCER. Many challenges for CER are germane to iCER because many 
of the threats to external validity in CER are due to individual unobserved confounders. In the 
future, researchers need to build on these methods and address (a) how to predict treatment 
responses while taking into consideration the patient’s preference and choice; and (b) what the 
empirical use of the iCER framework is in real world practice. 
 
More fundamental, perhaps, is the issue of appropriate theoretical framework for iCER. Most 
medical research on treatment response has been focused on testing the null hypothesis of zero 
average treatment effect (even in pre-specified subgroup analysis, the idea is the same). If 
researchers, clinicians and policy makers wish to inform treatment choice for a given individual or 
group, they should not view statistical insignificance as a reason to refrain from studying 
heterogeneity in treatment response. In other words, they should not treat the null and alternative 
hypothesis asymmetrically, fixing the probability of a type I error and seeking to minimize the 
probability of a type II error. Instead, they must be concerned with the quantitative variation of 
outcomes with treatments and covariates. Hypothesis testing simply does not address this problem.  
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